A detailed history of Geode Capital Management, LLC transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 813,489 shares of YMAB stock, worth $9.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
813,489
Previous 765,643 6.25%
Holding current value
$9.06 Million
Previous $9.25 Million 15.5%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$9.95 - $15.39 $476,067 - $736,349
47,846 Added 6.25%
813,489 $10.7 Million
Q2 2024

Aug 09, 2024

BUY
$11.6 - $17.25 $265,570 - $394,921
22,894 Added 3.08%
765,643 $9.25 Million
Q1 2024

May 13, 2024

BUY
$6.57 - $18.69 $27,600 - $78,516
4,201 Added 0.57%
742,749 $12.1 Million
Q4 2023

Feb 13, 2024

BUY
$4.88 - $7.42 $135,249 - $205,645
27,715 Added 3.9%
738,548 $5.04 Million
Q3 2023

Nov 13, 2023

SELL
$4.86 - $7.23 $4,038 - $6,008
-831 Reduced 0.12%
710,833 $3.87 Million
Q2 2023

Aug 11, 2023

BUY
$5.68 - $10.34 $278,427 - $506,856
49,019 Added 7.4%
711,664 $4.83 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $5.11 $88,723 - $160,203
31,351 Added 4.97%
662,645 $3.32 Million
Q4 2022

Feb 13, 2023

SELL
$3.0 - $15.17 $4,803 - $24,287
-1,601 Reduced 0.25%
631,294 $3.08 Million
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $93,908 - $132,320
6,727 Added 1.07%
632,895 $9.13 Million
Q2 2022

Aug 12, 2022

BUY
$8.22 - $15.13 $350,492 - $645,128
42,639 Added 7.31%
626,168 $9.47 Million
Q1 2022

May 13, 2022

SELL
$6.55 - $17.42 $245,284 - $652,344
-37,448 Reduced 6.03%
583,529 $6.93 Million
Q4 2021

Feb 11, 2022

BUY
$15.51 - $29.31 $680,361 - $1.29 Million
43,866 Added 7.6%
620,977 $10.1 Million
Q3 2021

Nov 12, 2021

BUY
$27.47 - $37.31 $715,978 - $972,447
26,064 Added 4.73%
577,111 $16.5 Million
Q2 2021

Aug 13, 2021

BUY
$25.45 - $37.64 $1.96 Million - $2.9 Million
76,929 Added 16.23%
551,047 $18.6 Million
Q1 2021

May 12, 2021

BUY
$29.16 - $51.96 $1.26 Million - $2.25 Million
43,240 Added 10.04%
474,118 $14.3 Million
Q4 2020

Feb 12, 2021

BUY
$37.86 - $54.26 $1.12 Million - $1.61 Million
29,701 Added 7.4%
430,878 $21.3 Million
Q3 2020

Nov 13, 2020

BUY
$35.13 - $43.62 $1.5 Million - $1.86 Million
42,614 Added 11.88%
401,177 $15.4 Million
Q2 2020

Aug 13, 2020

BUY
$23.66 - $49.53 $1.21 Million - $2.54 Million
51,241 Added 16.67%
358,563 $15.5 Million
Q1 2020

May 14, 2020

BUY
$14.39 - $35.8 $505,146 - $1.26 Million
35,104 Added 12.9%
307,322 $8.02 Million
Q4 2019

Feb 13, 2020

BUY
$23.81 - $33.78 $1.62 Million - $2.3 Million
68,016 Added 33.31%
272,218 $8.51 Million
Q3 2019

Nov 12, 2019

BUY
$21.57 - $31.37 $846,040 - $1.23 Million
39,223 Added 23.77%
204,202 $5.32 Million
Q2 2019

Aug 14, 2019

BUY
$19.51 - $28.31 $1.47 Million - $2.14 Million
75,509 Added 84.4%
164,979 $3.77 Million
Q1 2019

May 14, 2019

BUY
$18.21 - $26.21 $208,285 - $299,789
11,438 Added 14.66%
89,470 $2.35 Million
Q4 2018

Feb 13, 2019

BUY
$15.41 - $28.92 $1.2 Million - $2.26 Million
78,032 New
78,032 $1.59 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.